Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster.

Literature DB >> 7427624

Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster.

E de Clercq, H Degreef, J Wildiers, G de Jonge, A Drochmans, J Descamps, P de Somer.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 1980 PMID： 7427624 PMCID： PMC1714507 DOI： 10.1136/bmj.281.6249.1178

Source DB: PubMed Journal: Br Med J ISSN： 0007-1447

× No keyword cloud information.

4 in total

1. Pharmacokinetics of E-5-(2-bromovinyl)-2'-deoxyuridine in mice.

Authors: E de Clercq; J Descamps; P de Somer; P J Barr; A S Jones; R T Walker
Journal: Antimicrob Agents Chemother Date: 1979-08 Impact factor: 5.191

2. Parenteral acyclovir therapy for herpesvirus infections in man.

Authors: P J Selby; R L Powles; B Janeson; H E Kay; J G Watson; R Thornton; G Morgenstern; H M Clink; T J McElwain; H G Prentice; R Corringharn; M G Ross; A V Hoffbrand; D Brigden
Journal: Lancet Date: 1979-12-15 Impact factor: 79.321

3. (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent.

Authors: E De Clercq; J Descamps; P De Somer; P J Barr; A S Jones; R T Walker
Journal: Proc Natl Acad Sci U S A Date: 1979-06 Impact factor: 11.205

4. (E)-5-(2-bromovinyl)-2'-Deoxyuridine in the treatment of experimental herpes simplex keratitis.

Authors: P C Maudgal; E De Clercq; J Descamps; L Missotten; P De Somer; R Busson; H Vanderhaeghe; G Verhelst; R T Walker; A S Jones
Journal: Antimicrob Agents Chemother Date: 1980-01 Impact factor: 5.191

4 in total

23 in total

1. Novel ribofuranosylnucleoside lead compounds for potent and selective inhibitors of mitochondrial thymidine kinase-2.

Authors: J Balzarini; C Zhu; E De Clercq ; M J Pérez-Pérez; C Chamorro; M J Camarasa; A Karlsson
Journal: Biochem J Date: 2000-10-01 Impact factor: 3.857

2. Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase.

Authors: Anton Neschadim; James C M Wang; Takeya Sato; Daniel H Fowler; Arnon Lavie; Jeffrey A Medin
Journal: Mol Ther Date: 2012-01-24 Impact factor: 11.454

Review 3. Specific targets for antiviral drugs.

Authors: E De Clercq
Journal: Biochem J Date: 1982-07-01 Impact factor: 3.857

4. Susceptibility of vaccine strains of varicella-zoster virus to antiviral compounds.

Authors: S R Preblud; A M Arbeter; E A Proctor; S E Starr; S A Plotkin
Journal: Antimicrob Agents Chemother Date: 1984-04 Impact factor: 5.191

5. Regeneration of the antiviral drug (E)-5-(2-bromovinyl)-2'-deoxyuridine in vivo.

Authors: C Desgranges; G Razaka; F Drouillet; H Bricaud; P Herdewijn; E De Clercq
Journal: Nucleic Acids Res Date: 1984-02-24 Impact factor: 16.971

Review 6. Antiherpes drugs: promises and pitfalls.

Authors: E de Clercq
Journal: Eur J Clin Microbiol Date: 1984-04 Impact factor: 3.267

7. (E)-5-(2-bromovinyl)-2'-deoxyuridine-5'-triphosphate as a DNA polymerase substrate.

Authors: J Sági; A Szabolcs; A Szemzö; L Otvös
Journal: Nucleic Acids Res Date: 1981-12-21 Impact factor: 16.971

8. Effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine on proliferation of human fibroblasts, peripheral blood mononuclear cells, and granulocyte-monocyte progenitor cells in vitro.

Authors: A E Wittek; P S Cohen; A M Arvin; S D Smith; C M Koropchak; E De Clercq
Journal: Antimicrob Agents Chemother Date: 1983-11 Impact factor: 5.191

9. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.

Authors: E De Clercq; J Descamps; M Ogata; S Shigeta
Journal: Antimicrob Agents Chemother Date: 1982-01 Impact factor: 5.191

10. Inhibitory effects of antiherpesviral thymidine analogs against varicella-zoster virus.

Authors: H Machida; A Kuninaka; H Yoshino
Journal: Antimicrob Agents Chemother Date: 1982-02 Impact factor: 5.191